J 2019

Chronic Benign CD8+Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse

OSOVSKA, Marcela, Andrea JANÍKOVÁ, Leoš KŘEN a Andrea MAREČKOVÁ

Základní údaje

Originální název

Chronic Benign CD8+Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse

Autoři

OSOVSKA, Marcela (203 Česká republika), Andrea JANÍKOVÁ (203 Česká republika, domácí), Leoš KŘEN (203 Česká republika, domácí) a Andrea MAREČKOVÁ (203 Česká republika, domácí)

Vydání

CASE REPORTS IN HEMATOLOGY, LONDON, HINDAWI LTD, 2019, 2090-6560

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Kód RIV

RIV/00216224:14110/19:00109676

Organizační jednotka

Lékařská fakulta

UT WoS

000461613800001

Klíčová slova anglicky

Chronic benign CD8+ proliferation

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 8. 6. 2020 08:59, Mgr. Tereza Miškechová

Anotace

V originále

Chronic benign CD8+ proliferation is a rare syndrome that can take the form of a variety of other diseases. Peripheral adenopathy, cytopenia, and infiltration of the liver, kidneys, bowels, or other organs are the most common clinical presentations of the syndrome. CD8+ expansion can be clonal and nonclonal. It generally occurs in patients with innate or acquired immunodeficiency (HIV+) or in patients receiving immunosuppressive therapy. It has been found repeatedly in patients who developed severe hypogammaglobulinemia after treatment with rituximab. Diagnosis of the disease can be difficult because it can mimic relapse of a lymphoma, and a common biopsy examination cannot identify the problem at first. The authors describe a case of a patient pretreated with rituximab who developed agammaglobulinemia and peripheral adenopathy. Biopsy of an enlarged lymph node showed reactive lymphadenitis. Additionally, a flow-cytometric examination revealed a pathological population of CD8+ lymphocytes. The treatment, which differed from treatments of lymphoma relapse, consisted of corticosteroids and IVIG substitutions and has led to a regression of clinical symptoms. With more frequent usage of rituximab, one can expect increased occurrence of a very rare CD8+ expansion that can reliably emulate the relapse of a lymphoma.